No Data
Zhejiang CONBA Pharmaceutical Gets Registration Approval for Asthma Relief Drug
Zhejiang Conba Pharmaceutical (600572.SH): The subsidiary has obtained a pharmaceutical registration certificate for inhaled ipratropium bromide solution.
On January 16, Gelonghui reported that Zhejiang Conba Pharmaceutical (600572.SH) announced that its wholly-owned subsidiary, Zhejiang Jinhua Conba Pharmaceutical Co., Ltd., received the Drug Registration Certificate approved by the National Medical Products Administration for a 2ml: 0.5mg inhalation solution of ipratropium bromide. The inhalation solution of ipratropium bromide was originally developed by Boehringer Ingelheim and launched in the United Kingdom in 1986, and received approval for marketing in China in 2006. As a bronchodilator, the inhalation solution of ipratropium bromide is used for the maintenance treatment of bronchospasm caused by chronic obstructive pulmonary disease.
Zhejiang Conba Pharmaceutical (600572.SH): Subsidiary Enticavir tablets have received approval from the USA FDA.
On January 16, Glonghui reported that Zhejiang Conba Pharmaceutical's wholly-owned subsidiary, Jinhua Conba Pharmaceutical Co., Ltd., has established a wholly-owned subsidiary in the USA, Conba USA Inc (referred to as "USA Conba"). It received notification from the FDA that the abbreviated new drug application (ANDA, which is the USA generic drug application) for Entecavir tablets submitted by USA Conba has been approved. Entecavir tablets are a guanosine nucleoside analog that inhibit the polymerase of the Hepatitis B virus (HBV), suitable for conditions with active viral replication and serum.
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Market Cap Dropped CN¥752m Last Week; Individual Investors Bore the Brunt
Zhejiang Conba Pharmaceutical (600572.SH) appointed Chairman Jiang Yi to also serve as the company's president.
Zhejiang Conba Pharmaceutical (600572.SH) announced that the company's Board of Directors recently received a submission from the president Mr. Luo Guoliang...
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The Business
